Table 1.
Treatment | N | 2nd CR, % | Median duration 2nd CR, mo |
Median OS, mo |
---|---|---|---|---|
HDAra-C vs HDAra-C +Mit | 162 | 32 vs 44 | 9 vs 5 | 8 vs 6 |
EMA vs EMA + GM-CSF | 72 | 81 vs 89 | 4 vs 5 | 9 vs 10 |
MAE vs MAE + G-CSF | 129 | 25 vs 17 | 9 vs 10 | 5 vs 4 |
MEC vs MEC + lintuzumab | 191 | 23 vs 29 | NA | 8 vs 6 |
HDAra-C vs HDAra-C + laromustine | 178 | 19 vs 35 | 332 vs 275 d | 177 vs 128 d |
HDAra-C + Mit vs IDAC + Mit | 186 | 52 vs 45 | 5.3 vs 3.3 | 5 vs NA |
HDAra-C + Amsa vs HDAra-C + Mit | 52 | 53 vs 60 | 11 vs 12 | 8 vs 11 |
HDAra-C vs HDAra-C + Amsa | 36 | 14 vs 53 | NA | 2 vs 6 |
HDAra-C vs HDAra-C + Eto | 131 | 40 vs 45 | 12 vs 25 | 5 vs 5 |
Karanes, et al. Leuk Res. 1999;23:787–794; Thomas, et al. Leukemia. 1999; 13: 1214–1220; Greenberg, et al. J Clin Oncol. 2004;22: 1078–1086; Feldman, et al. J Clin Oncol. 2005;23:4110–4116; Giles, et al. Blood (ASH Annual Meeting Abstracts). 2006; 108. Abstract 1970; Kern, et al. Leukemia. 2000; 14:226–231; Martiat, et al. Eur J Haematol. 1990;45: 164–167; Larson, et al. Br J Haematol. 1992;82:337–346; Vogler, et al. Leukemia. 1994;8: 1847–1853; Ohno, et al. Blood. 1994;83:2086–2092